Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Investor Presentation (February 2024)
34 slides from Janux Therapeutics's investor presentation, Feb 26, 2024
Slide 1: Tumor Activated Cancer Therapeutics
Tumor Activated Cancer Therapeutics Restoring anti-tumor immune responses to treat cancer patients February 26, 2024 Exhibit 99.2
Slide 2: Forward-looking statements and disclaimers
Forward-looking statements and disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: Janux – multiple near-term high value opportunities in CD3 TCE targets
Janux – multiple near-term high value opportunities in CD3 TCE targets Clinical Pipeline Technology Platform Cash Position *As of September 30, 2023, includes cash and cash equivalents PSMAxCD3-TRACTr to treat mCRPC illustrating a potential best-in-class profile Promising efficacy with favorable saf
Slide 4: T-cell engagers – a strategy for creating potent anti-tumor immune responses
T-cell engagers – a strategy for creating potent anti-tumor immune responses Solid tumor treatments have been hindered by safety and PK challenges Limitations of conventional TCEs Conventional TCEs are not tumor specific and bind to all tissues expressing target Healthy tissue activity worsens CRS a
Slide 5: T-cell engagers – tumor activated TCEs as solution
T-cell engagers – a strategy for creating potent anti-tumor immune responses Solid tumor treatments have been hindered by safety and PK challenges Emerging PSMA & EGFR-TRACTr clinical data demonstrates efficacy with favorable safety profiles Tumor Proteases Limitations of conventional TCEs Conventio
Slide 6: Janux TRACTr platform design principles
Janux Tumor Activated T-Cell Engager (TRACTr) platform design principles Each program is designed as a potent T-cell engager with reduced toxicity Healthy Tissue Healthy Tissue Improved Safety Masks block binding to targets in healthy tissues Inhibits immune response against healthy tissues Reduces
Slide 7: JANX007 interim clinical PK data consistent with TRACTr design principles
JANX007 interim clinical PK data has been consistent with TRACTr design principles TRACTr activation without TCE accumulation observed TRACTr plasma levels consistent with ≥ once-weekly dosing JANX007 clinical PK data is consistent with tumor mediated TRACTr activation * Interim data from subject 11
Slide 8: JANX007 interim clinical PK data consistent with TRACTr design principles
JANX007 interim clinical PK data has been consistent with TRACTr design principles TRACTr activation without TCE accumulation observed TRACTr plasma levels consistent with ≥ once-weekly dosing sDa cleavage fragment indicates TRACTr activation is occurring JANX007 clinical PK data is consistent with
Slide 9: JANX007 interim clinical PK data consistent with TRACTr design principles
JANX007 interim clinical PK data has been consistent with TRACTr design principles TRACTr activation without TCE accumulation observed TRACTr plasma levels consistent with ≥ once-weekly dosing sDa cleavage fragment indicates TRACTr activation is occurring TCE plasma levels below preclinical activity
Slide 10: PSMA-TRACTr Program JANX007
PSMA-TRACTr Program JANX007
Slide 11: JANX007 phase 1 trial design in mCRPC
Male ≥18 years of age at the time of signing informed consent Histologically or cytologically confirmed adenocarcinoma of the prostate Documented progression after treatment with least 1 anti-androgen therapy and at least 1 taxane, or refused taxane therapy Adequate organ function Subjects not selec
Slide 12: Summary of preliminary data from ongoing Phase 1a trial of JANX007
Summary of preliminary data from ongoing Phase 1a trial of JANX007 Subjects with first step dose ≥ 0.2mg (n=6) Subjects with first dose ≥ 0.1mg (n=18) CRS No CRS > Grade 2 for any cohort PSA declines consistently observed after CRS Non-CRS related TRAEs Majority of TRAEs are low grade (G1/2) occurri
Slide 13: JANX007 subject characteristics
JANX007 subject characteristics Heavily pre-treated subjects with a median of 4+ lines of therapy 12 February 2024 data cutoff Characteristic All subjects, n = 23 Median age, years (range) 69 (46-75) Race White, n (%) 17 (74) Asian, n (%) 1 (4) Black, n (%) 4 (17) Number of prior lines of therapy, m
Slide 14: PSA responses deepening with increased doses while maintaining low grade CRS
PSA responses deepening with increased doses while maintaining low grade CRS CRS observed only in subjects with PSA reductions PSA reduction combined with low-grade CRS profile consistent with tumor specific activation CRS Grade * PSA decline observed after CRS occurrence Encouraging CRS profile Tra
Slide 15: JANX007 PSA reduction and CRS addresses limitations of prior PSMA-TCEs
JANX007 combination of PSA reduction and CRS addresses safety and efficacy limitations of prior PSMA-TCEs Low grade CRS maintained as dose-levels have been increased to deepen PSA responses Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison
Slide 16: Improved PSA responses observed at higher doses of JANX007
Improved PSA responses observed at higher doses of JANX007 Days post-1st infusion 1st step ≥ 0.2 mg cohorts achieve deeper and more durable PSA responses while maintaining low-grade CRS 12 February 2024 data cutoff % PSA change from baseline % PSA change from baseline Days post-1st infusion 0.1/0.3/
Slide 17: Prior therapies and time on JANX007 treatment for all subjects
Step Dose Cohorts QW QW Step Dose Cohorts Q2W target 0.1 mg 0.3 mg 0.05/0.1/0.3 mg Flat Dose Cohorts QW 0.1/0.3/1 mg 0.1/0.3/0.45 mg 0.1/0.3/1 mg 0.2/0.6/2 mg 0.2/0.6/2 mg 0.3/1/3 mg Prior therapies and time on JANX007 treatment for all subjects Tn PARP RL PRIOR THERAPIES: Tn: taxane; RL: 177Lu-TRT
Slide 18: Significant tumor burden reductions demonstrated by PSMA-PET
Significant tumor burden reductions demonstrated by PSMA-PET Subject 013 (cohort 4, 0.1/0.3/0.45mg) Past medical history Subject: 75-year-old Diagnosis: Nov 2020 with Gleason score 9, stage IVB Prior therapies: heavily treated with 6 prior lines of therapy JANX007 treatment history Best PSA decline
Slide 19: Treatment related adverse events in ≥2 subjects
Treatment related adverse events in ≥2 subjects Majority low-grade AEs occurring in cycle 1 of treatment Preferred Term All Subjects (n=23) Grade 1 Grade 2 Grade ≥3 All Grades Cytokine release syndrome 8 (35) 13 (57) 0 21 (91) Diarrhoea 6 (26) 2 (9) 0 8 (35) Chills 4 (17) 2 (9) 0 6 (26) ALT increase
Slide 20: Emerging clinical data highlights the competitive potential for JANX007
Emerging clinical data highlights the competitive potential for JANX007 JANX007 safety profile supports continued dose escalation to further enhance already notable efficacy Characteristic JANX007 (n=18) JANX007 (n=6) AMG509 (n=44) STEAP1xCD3 ARX517 (n=23) PSMA-ADC Selected cohorts 1st dose ≥ 0.1mg
Slide 21: JANX007 positioning in mCRPC
JANX007 positioning in mCRPC Target PSMA is a clinically validated (Pluvicto®) and highly expressed target that is expressed in >80%† of mCRPC patients JANX007 Single-agent efficacy and safety data in heavily pre-treated, late-stage mCRPC patients Supports single-agent development in 3L+ and 2L+ set
Slide 22: Substantial market potential for a best-in-class TCE in mCRPC
There is substantial market potential for a best-in-class TCE in mCRPC JANX007 Potential Market Opportunity 2L+ (27k) 3L+ (18k) 1L (42k) Metastatic Castration Resistant Prostate Cancer (~70k) Enza, abi, chemo Abi, chemo, enza, Pluvicto®, Xofigo®, PARP Chemo, Pluvicto®, pembro, Xofigo®, abi, enza ~$2
Slide 23: EGFR-TRACTr Program JANX008
EGFR-TRACTr Program JANX008
Slide 24: JANX008 Phase 1 trial design in NSCLC, SCCHN, CRC, and RCC
Objectives Eligibility Criteria JANX008 Phase 1 trial design in NSCLC, SCCHN, CRC, and RCC Subjects ≥18 years of age at the time of signing informed consent Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, or RCC Progressed or was intolerant to all availab
Slide 25: Summary of preliminary data from ongoing Phase 1a trial of JANX008
Summary of preliminary data from ongoing Phase 1a trial of JANX008 Confirmed RECIST partial response with 100% target lesion reduction in a subject with NSCLC at 0.15mg RECIST response ongoing at 18 weeks* Elimination of hepatic metastasis Anti-tumor activity coupled with no CRS or TRAEs observed in
Slide 26: JANX008 subject characteristics
JANX008 subject characteristics Heavily pre-treated subjects with an average of 4+ lines of therapy, the majority having failed anti-PD-(L)1 treatment Characteristic All subjects n = 11 NSCLC n = 4 CRC n = 4 RCC n = 2 SCCHN n = 1 Median age, years (range) 65 (37 – 81) 67.5 (62 – 71) 53 (37 – 72) 61.
Slide 27: Time on treatment for all subjects
Time on treatment for all subjects - End of Treatment - On treatment 0.05 mg 0.15 mg 0.5/1.25 mg Flat Dose Cohorts QW Step Dose Cohorts QW 1 mg SD Confirmed PR SD SD CRC CRC CRC RCC RCC NSCLC NSCLC NSCLC NSCLC SCCHN - Best RECIST response 100% decease size of TL and elimination of hepatic metastasis
Slide 28: Confirmed PR in a heavily pretreated subject with NSCLC
Past medical history Subject: 62-year-old male Diagnosis: Feb 2021 with NSCLC, adeno, Stage IIIB Mutations: MSI-L/MSS, MET, TP53 4L prior Tx, PD-(L)1 refractory JANX008 treatment summary Cycle 1 Day 1: 11 Oct 2023 Active on therapy JANX008 CRS and TRAE summary No CRS or TRAEs observed Confirmed RECI
Slide 29: Early anti-tumor activity observed in a subject with RCC
Early anti-tumor activity observed in a subject with RCC Subject 21011 (0.5/1.25 mg QW) Past medical history Subject: 42-year-old male Diagnosis: Jan 2023 with RCC, clear cell, stage IV Mutations: MSI-L/MSS, pMMR Prior therapies: three prior lines of therapy JANX008 treatment summary Cycle 1 Day 1:
Slide 30: Encouraging anti-tumor activity observed in early cohorts
Encouraging anti-tumor activity observed in early cohorts Activity in heavily pre-treated, late-stage subjects underscores JANX008 opportunity in large market indications 0.05 mg 0.15 mg 0.5/1.25 mg Flat Dose Cohorts QW Step Dose Cohorts QW Best Response per RECIST v1.1 PD PD SD PD SD SD NE cPR NSCL
Slide 31: Treatment related adverse events
Treatment related adverse events Majority of low-grade AEs occurred only in cycles 1 and 2 TRAE Preferred Term All Subjects (n=11) Grade 1 Grade 2 Grade ≥3 All Grades Arthralgia 3 (27) 0 0 3 (27) Anemia 0 1 (9) 1 (9) 2 (18) Cytokine release syndrome 2 (18) 0 0 2 (18) Dermatitis acneiform* 2 (18) 0 0
Slide 32: Combination of efficacy and safety enables opportunity in multiple large indications
Combination of efficacy and safety enables opportunity to treat multiple large patient indications Additional Opportunities Breast Bladder Ovarian Liver Pancreas 50% - 90% ~80% 73% - 94% 90% - 95% NSCLC CRC RCC SCCHN $2B+ $4B+ $2B+ $4B+ EGFR Overexpression JANX008 Potential Market Opportunity
Slide 33: Janux clinical update summary
Janux clinical update summary Proof of Principle Large Opportunity Forward Momentum PSMA and EGFR-TRACTr clinical programs showcase an early display of efficacy combined with a differentiated favorable safety profile in heavily pre-treated, late state cancer patients Clinical data provides compellin
Slide 34: David Campbell, Ph.D. President and CEO
David Campbell, Ph.D. President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 dcampbell@januxrx.com
Janux Therapeutics — Investor Presentation (February 2024) on 6ix